Valuation metrics show AbbVie to be only slightly undervalued based on FY 2025 projections. Read why I'm neutral on ABBV ...

Chicago, IL – October 22, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks ...

AbbVie, a global, research-driven biopharmaceutical company, organized a visit to its R&D facilities—the AbbVie Cambridge ...

Monday announced that nine provinces have approved accelerated public coverage of Epkinly, a treatment for adult ...

Regenxbio and AbbVie announced positive Phase II results for gene therapy ABBV-RGX-314 in wet AMD, showing a 97% reduction in ...

AbbVie (NYSE: ABBV) today announced that nine provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...

Cannon Financial Strategists Inc. decreased its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 2.4% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund ...

A minorities-only study on a dual-action therapy for diabetic macular edema found Hispanic and Latino patients not only ...

Progressive pulmonary fibrosis (PPF) is an increasingly recognised condition, defined in 2022 to address the progression of ...

NEW YORK, Oct. 21, 2024 /PRNewswire/ -- Report with the AI impact on market trends- The global sexually transmitted disease ...

In patients with moderate to severe Crohn’s disease, guselkumab showed similar efficacy in both biologic-naive and ...

Regenxbio (RGNX) announced positive data from the Phase II fellow eye sub-study evaluating the subretinal delivery of ABBV-RGX-314 in patients ...